Genentech Submits Application To FDA For Trastuzumab-DM1 In Previously Treated Advanc
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies...
More... |
All times are GMT -7. The time now is 02:07 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021